๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Midazolam in patients receiving anticancer chemotherapy and antiemetics

โœ Scribed by Lisa M. Potanovich; Katherine M.W. Pisters; Mark G. Kris; Leslie B. Tyson; Rebecca A. Clark; Lorraine Baltzer; Richard J. Gralla

Book ID
113382090
Publisher
Elsevier Science
Year
1993
Tongue
English
Weight
606 KB
Volume
8
Category
Article
ISSN
0885-3924

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Antiemetics in children receiving chemot
Antiemetics in children receiving chemotherapy
โœ Fausto Roila; Petra Feyer; Ernesto Maranzano; Ian Olver; Rebecca Clark-Snow; Dav ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› Springer-Verlag ๐ŸŒ English โš– 95 KB
Antiemetics in children receiving chemot
Antiemetics in children receiving chemotherapy
โœ Fausto Roila; Petra Feyer; Ernesto Maranzano; Ian Olver; Rebecca Clark-Snow; Dav ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› Springer-Verlag ๐ŸŒ English โš– 40 KB
Dose-ranging antiemetic evaluation of th
Dose-ranging antiemetic evaluation of the serotonin antagonist rg 12915 in patients receiving anticancer chemotherapy
โœ Lorraine Baltzer; Mark G. Kris; Leslie B. Tyson; James R. Rigas; Katherine M. W. ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 484 KB

Background. RG 12915 is a potent, selective 5-HT3 receptor antagonist with a biologic half-life of 31-20 hours. RG 12915 prevents cisplatin-induced emesis in ferrets at doses of 0.03 mg/kg. Animal toxicology studies permitted safe testing in humans at doses of up to 2.0 mg/kg. This dose-ranging tria